Mycobacterium tuberculosis Cell Wall Fragments for Tuberculosis Prophylaxis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current primary chemoprophylaxis for tuberculosis using isoniazid has significant side effects and compliance issues due to prolonged administration, which can last up to 12 months, making it unsatisfactory for effective prevention of infection in individuals exposed to M. tuberculosis.
Innovation Solution
An immunotherapeutic agent comprising cell wall fragments of a virulent strain of Mycobacterium tuberculosis-complex (MTB-C) is used for primary prophylaxis, prepared by culturing the virulent strain, homogenizing the cells with a nonionic surfactant, separating and inactivating the fragments, and lyophilizing them for administration as liposomes, which can be given in a shorter duration and with fewer side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If primary chemoprophylaxis using isoniazid is administered for prolonged periods (up to 12 months), then prevention of tuberculosis infection is achieved, but side effects increase and compliance becomes difficult
Solution Approach 1:
The patent changes the fundamental parameter of the prophylactic agent from a chemical drug (isoniazid) to an immunotherapeutic agent based on cell wall fragments of M. tuberculosis. This parameter change allows achieving prevention effectiveness through immunological mechanisms rather than prolonged chemical suppression, thereby reducing side effects and treatment duration requirements.
Solution Approach 2:
The patent replaces the chemical suppression mechanism (isoniazid acting on bacterial cell synthesis) with an immunological mechanism (cell wall fragments inducing protective immune response). This substitution eliminates the need for prolonged administration and reduces harmful side effects associated with chemical drugs.
2Reliability
If primary chemoprophylaxis using isoniazid is administered for prolonged periods (up to 12 months), then prevention of tuberculosis infection is achieved, but compliance becomes difficult
Solution Approach 1:
The patent changes the treatment approach from prolonged chemical administration to a shorter-duration immunotherapeutic intervention. This parameter change in treatment duration fundamentally improves compliance by reducing the time patients must adhere to a strict medication regimen.
Solution Approach 2:
The patent substitutes chemical suppression with immunological protection, which provides longer-lasting protection without requiring continuous medication intake. This substitution naturally improves compliance as patients do not need to maintain prolonged daily dosing schedules.
3Reliability
If conventional BCG vaccine is used for primary prophylaxis, then tuberculosis prevention is provided, but protective response is insufficient compared to virulent strain fragments
Solution Approach 1:
The patent inverts the traditional vaccine approach by using fragments from a virulent strain rather than an attenuated strain. This inversion of the strain characteristic produces a more potent protective response, as the immune system is exposed to the actual structural features of the pathogen rather than a weakened version.
Solution Approach 2:
The patent uses cell wall fragments as a simplified copy or representation of the virulent M. tuberculosis strain. These fragments contain the essential immunogenic structures that trigger protective immunity, providing an effective prophylaxis without requiring the full virulent organism or its complex attenuation process.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The immunotherapeutic agent provides a more effective protective response against M. tuberculosis infection than the conventional BCG vaccine, reducing the number of viable bacilli in infected individuals and potentially eradicating the bacillus population, thus offering a superior primary prophylaxis against tuberculosis.
Implementation Method 1
homogenizing the cell culture in the presence of a nonionic surfactant
Implementation Method 2
lyophilizing them for administration as liposomes
Data Source
AI summary
The present invention relates to the use of an immunotherapeutic agent having cell wall fragments of a virulent strain of Mycobacterium tuberculosis for the preparation of a drug suitable for the primary prophylaxis of tuberculosis. The immunotherapeutic agent is capable of inducing a protective response that is more effective than the conventional BCG vaccine and reduces the number of viable bacilli in the lungs and in the spleen of individuals recently infected by M. tuberculosis.